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Cell-mediated immunity plays a major role in conferring protection against tuberculosis (TB) on an individual.
It is not known whether the immune status correlates with the bacterial load or whether the immunity improves
after treatment. Also, it may be important to monitor treatment by being able to discriminate between active disease
and successfully treated TB. The main aim of this study was to investigate the usefulness of a recombinant 32-kDa
antigen (r32-kDa Ag) of Mycobacterium bovis BCG (Ag85A-BCG) as a diagnostic marker in patients being treated
for TB. Specifically, the in vitro T-cell assays and the release of interleukin-12 (IL-12) (Th1-type cytokine) and IL-10
(Th2-type cytokine) in response to the r32-kDa Ag of BCG were assayed in patients with either pulmonary (sputum
positive/negative, n  74) or extrapulmonary TB (n  49) and healthy controls. The proliferative responses of
stimulated cells at 0, 2 to 4, and 6 months of treatment increased and were highly significant (P< 0.000) compared
to the responses in controls. The increase in IL-12 and decrease in IL-10 release suggest that there is cytokine
expression modification during different stages of TB, and treatment seems to have an influence on the levels of
these cytokines, suggesting an augmentation in the protective responses. The in vitro response to theM. bovis BCG
r32-kDa Ag may be useful in monitoring treatment of TB.
Tuberculosis (TB) remains a major global health problem.
Mycobacterium tuberculosis infects one-third of the world’s
population, causing approximately 8 million new cases and 3
million deaths per year (4, 22). Since it is established that
cell-mediated immunity plays a major role in conferring pro-
tection against TB on an individual and that the immunity of a
patient with TB is compromised, an immunological test which
reflects the clinical status of an individual is warranted. On the
other hand, a test which discriminates between a patient with
active disease and a successfully treated person may be useful
in monitoring treatment.
We demonstrated earlier that the tuberculin skin test is not
a good indicator of immune status (27, 28, 29). The study was
conducted in India, a region with environmental mycobacteria
where TB is endemic and the Mycobacterium bovis BCG vac-
cine is routinely administered to children. This endemicity may
also influence the sensitivity of an assay which involves mea-
surement of gamma interferon (IFN-) concentrations in-
duced by purified protein derivative (27), ESAT-6, and/or
CFP-10 (17). The assay appears to be only as sensitive as the
tuberculin skin test (17). Furthermore, in the context of the
rising prevalence of drug-resistant TB, immunotherapy in con-
junction with antibiotics may gain importance in the control of
the disease. Therefore, there is a need to identify a mycobac-
terial immunogenetic protein.
Many cytokines are being evaluated as surrogate markers for
successful TB therapy, as the balance between Th1 and Th2
cytokines is likely to determine the fate of the infection (18).
The pretreatment biomarkers may perhaps be useful during
early treatment, which could help in identifying relapsing pa-
tients. Moreover, the biomarkers possibly will also aid in
grouping patients for enhanced clinical treatment administra-
tion (30). The antigen 85 (Ag85) complex of mycobacteria is a
major secretory product and has been found to induce T-cell
proliferation and antibody synthesis against TB (20, 32). The
results of our earlier studies based on an in vitro T-cell assay
using a recombinant 32-kDa Ag (r32-kDa Ag) of Mycobacte-
rium bovis BCG (Ag85A-BCG) revealed high levels of IFN-
levels in BCG-vaccinated children, indicating its effectiveness
both as a booster vaccine (1, 2) and for use in in vitro tests, by
virtue of being immunogenic. Hence, the present study inves-
tigates the influence of the r32-kDa Ag Ag85A-BCG on the in
vitro stimulation and activation of lymphocyte proliferative
responses and the production of interleukin-12 (IL-12) (Th1
type) and IL-10 (Th2 type) cytokines in patients with TB.
MATERIALS AND METHODS
Materials. A total of 153 subjects were included in the study, 74 with pulmo-
nary TB (PTB) and 49 with extrapulmonary TB (EPTB) who attended a Free
Chest DOTS Clinic (directly observed therapy—short course) at Mahavir Hos-
pital and Research Center between January 2004 and February 2007 and 30
asymptomatic, healthy volunteers. The criteria used for the diagnosis were spu-
tum smear microscopy and chest X ray for PTB and histopathology examination
of tissue biopsy for EPTB. The tuberculin skin test was not performed in all
patients and controls (27, 28, 29). All the individuals in the control group had a
BCG scar. At the time of preparation of the manuscript, response to anti-TB
treatment shown by alleviation of symptoms, sputum conversion, and weight gain
further reiterated the diagnosis of TB in these patients. The subjects were
stratified into seven groups (numbers of patients in groups are mentioned in
parentheses): (i) PTB-0 (34) and (ii) EPTB-0 (33), at the time of diagnosis; (iii)
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PTB-2/4 (19) and (iv) EPTB-2/4 (10), at between 2 and 4 months of treatment;
(v) PTB-6 (21) and (vi) EPTB-6 (6), after completion of treatment (6 months)
and cured; and (vii) controls (30). The study was approved by the Institutional
Ethics Committee. Peripheral venous blood was collected from all the subjects
after an informed consent was obtained from them.
Mycobacterium bovis BCG r32-kDa Ag.M. bovis r32-kDa Ag was synthesized as
described earlier (1, 2).
PBMC proliferation assay. The peripheral blood mononuclear cell (PBMC)
proliferation assay was performed as described earlier (1, 2). Briefly, PBMCs
were isolated from heparinized blood by density gradient centrifugation using a
Histopaque-1077 (Sigma, St. Louis, MO). Cells were then cultured in RPMI
1640 complete medium (Invitrogen Corporation, Grand Island, NY) at a con-
centration of 1  106 cells/ml (Falcon Products, Becton Dickinson, Oxnard, CA)
and stimulated with either 4 l (3 mg/ml) M. bovis BCG r32-kDa Ag or 30 l (1
mg/ml) concanavalin A (Sigma Aldrich, St. Louis, MO), the latter as a positive
control for cell reactivity. The cells were incubated for 5 days and 3 days,
respectively, at 37°C in an atmosphere of 5% CO2. Supernatants were collected
and stored at 80°C for further studies. After the addition of MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], the optical density
(OD) was recorded by using an enzyme-linked immunosorbent assay plate
reader (Anthos HT II; Anthos Labtec Instruments, Salzburg, Austria) using a
dual wavelength of 570 nm with a 620-nm reference filter. Data were expressed
as the stimulation index (SI), i.e., the ratio of the mean OD of experimental
cultures to the mean OD of control cultures, which was considered positive if the
value was 2.
IL-12p40 and IL-10 assay. To measure the concentrations of IL-12 and IL-10
in culture supernatants with a positive SI, an enzyme-linked immunosorbent
assay was performed using kits for cytokine detection (BD Opt EIA for human
IL-12, catalogue no. 555171, and for human IL-10, catalogue no. 555157; BD
Biosciences, San Diego, CA). The preparation of all reagents and the working
standards and protocol were according to the manufacturer’s instructions. The
antibody pairs used were capture antibody (anti-human IL-12 and IL-10 mono-
clonal antibodies) and detection antibody (biotinylated anti-human IL-12 and
IL-10 monoclonal antibodies).
Statistical analysis. The data were analyzed using Statistical Package for
Social Sciences (SPSS) statistical software (version 11.1). The results are
presented as means and standard deviations (SD); the Kruskal-Wallis test
and analysis of variance were used to compare the differences between the
groups. A difference was considered statistically significant if the P value was
0.05. The median results were also calculated, and they were similar to the
mean values.
RESULTS
PBMC proliferative responses induced by the M. bovis BCG
r32-kDa Ag. When stimulated with concanavalin A, 86% of
patients with both PTB and EPTB and 100% of healthy con-
trols had positive proliferative responses (data not shown).
When stimulated with the Ag, 67% of all patients and 100% of
the healthy group had positive SI values. The mean values for
the PTB-0, EPTB-0, and PTB-2/4 groups (2.66  0.55 [ SD],
2.59  0.43, and 3.38  0.94, respectively) were significantly
low (P  0.000) compared with the mean value for the control
group (4.51  1.09) (Fig. 1).
IL-12p40 release assays in patients and healthy controls
after in vitro stimulation with M. bovis BCG r32-kDa Ag. The
IL-12p40 levels in the PTB-0 (119  4.62 pg/ml) and EPTB-0
(127.1  1.87 pg/ml) groups were significantly lower than the
corresponding value (155.8  7.06 pg/ml) in the control group
(P  0.000). The mean values for the PTB-2/4, EPTB-2/4,
PTB-6, and EPTB-6 groups (137.3  1.65 pg/ml, 137.5  0.86
pg/ml, 144.3  2.63 pg/ml, and 145.7  2.17 pg/ml, respec-
tively) were also highly significant compared with the mean
value for the control group (155.8  7.06 pg/ml) (for PTB-2/4,
P 0.000; for EPTB-2/4, P 0.028; for PTB-6, P 0.001; and
for EPTB-6, P  0.017) (Fig. 2). The lowest mean value ob-
served was for the PTB-0 group, while the highest was for the
control group.
IL-10 release assays in patients and healthy controls after in
vitro stimulation with M. bovis BCG r32-kDa Ag. The mean
IL-10 level in the controls (39.70  7.36 pg/ml) was signifi-
cantly low compared to the levels in PTB-0 (88.9 13.8 pg/ml)
and EPTB-0 patients (67.1 8.63 pg/ml) (P 0.000); PTB-2/4
(57.2  4.0 pg/ml) and EPTB-2/4 patients (55  1.97 pg/ml)
(P  0.010); and PTB-6 (49.12  3.82 pg/ml) (P  0.000) and
EPTB-6 patients (48.8  1.44 pg/ml) (P  0.002) (Fig. 3).
FIG. 1. SIs of lymphoproliferative assay results for different clin-
ical categories of patients with TB and healthy controls after in vitro
stimulation with r32-kDa Ag of M. bovis BCG. Dots represent SIs.
Diamonds with vertical bars represent mean  SD of results for
each group. Results are shown for the following groups (with the
number of patients in the group in parentheses): PTB-0 (34) and
EPTB-0 (33), PTB-2/4 (19) and EPTB-2/4 (10), PTB-6 (21) and
EPTB-6 (6), and healthy controls (30). The P value was 0.000 for
control group results versus PTB-0, EPTB-0, and PTB-2/4 group
results.
FIG. 2. Mean IL-12 levels in supernatants of r32-kDa Ag-stim-
ulated PBMCs from 65 TB patients in different clinical categories
and from healthy controls. Dots represent levels in pg/ml. Dia-
monds with vertical bars represent mean  SD of results for each
category. Results are shown for the following groups (with the
number of patients in the group in parentheses): PTB-0 (24) and
EPTB-0 (9), PTB-2/4 (7) and EPTB-2/4 (3), PTB-6 (6) and EPTB-6
(5), and healthy controls (11). P values were 0.000 for control
group results versus PTB-0, EPTB-0, and PTB-2/4 group results;
0.028 for control group results versus EPTB-2/4 group results; 0.001
for control group results versus PTB-6 group results; and 0.017 for
control group results versus EPTB-6 group results.
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Contrary to the proliferation (SI) and IL-12 levels, the lowest
level was seen in the control group and the highest in the
PTB-0 group.
The mean levels of IL-12p40 and IL-10 at the time of diag-
nosis were 125 6.3 pg/ml and 79 1.6 pg/ml, respectively, for
all patients and 156  7.1 pg/ml and 40  7.4 pg/ml, respec-
tively, for controls, and the IL-12p40/IL-10 ratio for patients
was 1.58. The ratios increased after 2 to 4 months and after 6
months of treatment (2.36 and 2.8, respectively) (P  0.05)
(Fig. 4).
DISCUSSION
The Ag85 complex which has been the focus of study over
the past several years comprises three closely related proteins,
85A (32 kDa), 85B (30 kDa), and 85C (32.5 kDa) (1, 2, 16, 31,
32). The complex induces T-cell proliferation in PBMCs from
healthy tuberculin reactors and might become a candidate for
use as a sensitive marker for clinical status of the patient or a
novel TB vaccine (7, 9, 25). Indeed, MVA85A, a recombinant
modified vaccinia virus Ankara expressing Ag 85A, is the first
candidate TB subunit vaccine to enter human trials since BCG
was first introduced over 80 years ago. However, its potential
use as an in vitro correlate of protection has yet to be estab-
lished (12). In a study conducted by us with children, the in
vitro response seemed to reflect the clinical status of the child
(1, 2). It was demonstrated that the response of patients to this
85A Ag was significantly lower than that of healthy controls.
This being a region where TB is endemic, the majority of
individuals are exposed to environmental mycobacteria. Fur-
thermore, the controls in this study were BCG vaccinated.
The proliferative response toward M. bovis BCG r32-kDa
Ag in all the patients with PTB and EPTB was enhanced after
completion of treatment in this study, suggesting improve-
ments in cell-mediated immunity. Similarly, Jo et al. (10) re-
ported that the lymphoproliferative response to either the 30-
or 32-kDa Ag of M. tuberculosis increased in all patients after
2 months of treatment (10). Furthermore, Boesen et al. re-
ported that patients with active advanced TB exhibit a de-
pressed immune response to mycobacterial Ags (3). In another
study, low proliferative responses against recombinant M. tu-
berculosis 10-kDa, 30-kDa, 32-kDa, and 60-kDa Ags were re-
ported in PBMCs from TB patients (13). The depressed re-
sponses may be due to the suppressive factors secreted by
monocytes and lymphocytes and may also be due to a shift
from the Th1 to the Th2 type of cytokine response (11, 13, 15,
19). Immunosuppression may also be due to the preferential
sequestration of Ag-specific T cells into the infected areas,
leading to their absence in peripheral blood (24).
Furthermore, augmentation was also observed in the in vitro
release of IL-12 in relation to treatment in the present study.
IL-12 might play a crucial role by regulating IFN- production
and the cytotoxic effector function of mycobacterial Ag-specific
T cells (26, 33, 34, 35). The results of a study by Fulton et al.
(5) suggested that IL-12 released by infected macrophages can
in turn further upregulate M. tuberculosis-specific CD4 T-cell
effector function (5). A longitudinal study by Song et al. (23)
also reported observations for the 30- or 32-kDa Ag of M.
tuberculosis that were similar to those of the present study,
suggesting that the early stage of active PTB may be associated
with depressed IL-12 expression. Based on these results, Song
et al. and Fulton et al. furthermore hypothesized that patients
with active TB show increased IL-12 production after therapy
due to an afferent feedback signal of IFN- and that the re-
sultant IL-12 can upregulate more IFN- (6, 23).
The high levels of IL-10 observed in patients in this study
decreased in those who were cured, albeit not to the levels
seen in healthy subjects. Likewise, Song et al. also illustrated
high levels of IL-10 production in some patients stimulated
with 30- or 32-kDa Ag, though the levels were not significant
compared with those in healthy tuberculin reactors (23).
Increased levels of IL-10 in response to 30-kDa Ag of M.
tuberculosis in TB patients were demonstrated by Torres et
al. (25), suggesting that high levels of IL-10 may be due to
decreased blastogenic response and IFN- production dur-
FIG. 4. Means and ratios of IL-12/IL-10 levels (pg/ml) in superna-
tants of M. bovis BCG r32-kDa Ag-stimulated PBMCs over duration of
treatment for all the categories of patients in comparison with controls.FIG. 3. Mean IL-10 levels in supernatants of r32-kDa Ag-stimu-
lated PBMCs from 78 TB patients in different clinical categories and
from healthy controls. Dots represent levels in pg/ml. Diamonds with
vertical bars represent mean SD of results for each category. Results
are shown for the following groups (with the number of patients in the
group in parentheses): PTB-0 (28) and EPTB-0 (14), PTB-2/4 (10) and
EPTB-2/4 (2), PTB-6 (9) and EPTB-6 (3), and healthy controls (12). P
values were 0.000 for results for control group versus PTB-0,
EPTB-0, and PTB-6 groups; 0.010 for results for control group ver-
sus those for PTB-2/4 and EPTB-2/4 groups; and0.002 for results for
control group versus those for EPTB-6 group.
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ing active TB (25). In another study, conducted by Hirsch
et al. (8), the levels of IL-10 in sera and PBMCs from TB
patients in response to M. tuberculosis Ags were high (8).
The decrease in IL-10 release suggests that there might be a
modification of cytokine expression during different stages
of TB, and treatment seems to have an influence on the
levels of cytokines, with IL-12, a Th1 cytokine, increasing
and IL-10, a Th2 cytokine, decreasing, suggesting an aug-
mentation in the protective responses. These changes are
probably related to the Ag load, which decreases after treat-
ment (14, 20). No data for EPTB patients were reported by
other studies with respect to the 32-kDa Ag. In the present
study, the ratios of the IL-12/IL-10 levels in PTB and EPTB
patients increased with treatment. In contrast, in a study
conducted by Sahiratmadja et al. (21), the IL-12/IL-10 ratio
decreased at the end of the therapy, whereas the IFN-/
IL-10 ratio showed a slight increase at the end of therapy,
suggesting a shift toward a proinflammatory host immune
phenotype during control of infection (21).
These results strongly suggest that the balance in the Th1
and Th2 cytokines might play a major role in the clinical
outcome for the patient. Among the groups, the sputum-pos-
itive group had the lowest immune response (least prolifera-
tion, lowest IL-12 levels, and highest IL-10 levels). Follow-up
of all patients soon after treatment is completed may help in
identifying patients who are probably cured and, more impor-
tant, those who are likely to return to the clinic to be catego-
rized as “retreatment cases.” In other words, an early diagnosis
of the “retreatment cases” may help in monitoring treatment
and may have an impact on the national program (category II
according to the Revised National Tuberculosis Control Pro-
gramme [RNTCP] classification; the RNTCP is a comprehen-
sive strategy for TB control in India).
In conclusion, the level of in vitro response to the r32-kDa
Ag of M. bovis BCG leading to the release of IL-12 seems to
reflect the clinical status of the patient. Further studies may
indicate the use of this Ag in in vitro tests to assess the treat-
ment outcome.
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